Morris Plains-based Immunomedics Inc. announced Tuesday it has received a patent related to antibody research.

According to the announcement, the company received U.S. patent no. 8,617,558 for additional claims under the patent family "Camptothecin-binding moiety conjugates," and U.S. patent no. 8,617,518 with additional claims for the patent family "Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules."

Patent 8,617,558 relates to our proprietary linker technology for conjugating SN-38 to the Company's humanized antibodies for targeted delivery of the potent drug to the tumor. The patent will expire in December 2023, the company said in a statement.

[Release]

Stay informed: Subscribe to free NJBIZ newsletters